Coherus BioSciences, Inc. announced that it has entered into an asset purchase agreement dated December 2, 2024, with Intas Pharmaceuticals Ltd. for the divestiture of the Udenyca (pegfilgrastim-cbqv)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
